Muscle fat-fraction and mapping in Duchenne muscular dystrophy: Evaluation of disease distribution and correlation with clinical assessments preliminary experience

Skeletal Radiology

Volumn 41, Issue 8, 2012, Pages 955-961

  Gaeta, Michele ^a   Messina, Sonia ^a   Mileto, Achille ^a   Vita, Gian Luca ^a   Ascenti, Giorgio ^a   Vinci, Sergio ^a   Bottari, Antonio ^a   Vita, Giuseppe ^a   Settineri, Nicola ^a   Bruschetta, Daniele ^a   Racchiusa, Sergio ^a   Minutoli, Fabio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Clinical assessments; Color coded maps; Dual echo dual flip angle MRI technique; Duchenne muscular dystrophy; Muscle fat fraction; Timed Gower score

Indexed keywords

ADDUCTOR MAGNUS MUSCLE; ADOLESCENT; ARTICLE; BICEPS FEMORIS MUSCLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; DUAL ECHO DUAL FLIP ANGLE SPOILED GRADIENT RECALLED MAGNETIC RESONANCE IMAGING; DUCHENNE MUSCULAR DYSTROPHY; GLUTEUS MAXIMUS MUSCLE; GRACILIS MUSCLE; HUMAN; MALE; MUSCLE FAT FRACTION; MUSCULOSKELETAL SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECTUS FEMORIS MUSCLE; SCHOOL CHILD; SEMITENDINOUS MUSCLE; SKELETAL MUSCLE; THIGH; VASTUS LATERALIS MUSCLE; VASTUS MEDIALIS MUSCLE;

ADIPOSE TISSUE; ADIPOSITY; ADOLESCENT; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PELVIS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; THIGH;

EID: 84863980950     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-011-1301-5     Document Type: Article

References (27)

1. Dubowitz V. The muscular dystrophies. In: Muscle disorders in childhood. 2nd ed. London: Saunders, 1995;39-42.
2. Mercuri E, Mayhew A, Muntoni F, et al. On behalf of the TREAT-NMD Neuromuscular Network. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREATNMD/ENMC workshop on outcome measures, 12th-13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June-1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord. 2008;18:894-903.
3. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. The design of the protocol. Muscle Nerve. 1981;4:186-97. (Pubitemid 11098499)
4. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve. 1982;5:291-301. (Pubitemid 12070783)
5. Florence JM, Pandya S, King WM, et al. Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther. 1992;72:115-22.
6. Mayhew JE, Florence JM, Mayhew TP, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007;35:36-42. (Pubitemid 46052646)
7. Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009;19:458-61.
8. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20:712-6.
9. Schreiber A, Smith WL, Ionasescu V, et al. Magnetic resonance imaging of children with Duchenne muscular dystrophy. Pediatr Radiol. 1987;17:495-7. (Pubitemid 17158243)
10. Liu GC, Jong YJ, Chiang CH, Jaw TS. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology. 1993;186:475-80.
11. Marden FA, Connolly AM, Siegel MJ, Rubin DA. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol. 2005;34:140-8. (Pubitemid 40305454)
12. Huang Y, Majumdar S, Genant HK, et al. Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging. 1994;4:59-64.
13. Phoenix J, Betal D, Roberts N, Helliwell TR, Edwards RH. Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve. 1996;19:302-10. (Pubitemid 26069360)
14. Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology. 2010;225:899-908.
15. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol. 2008;190:W8-12.
16. Gaeta M, Scribano E, Mileto A, et al. Muscle fat fraction in neuromuscular disorder: dual-echo dual-flip-angle spoiled gradient-recalled MR imaging technique for quantification-a feasibility study. Radiology. 2011;259:487-94.
17. Gaeta M, Mileto A, Mazzeo A, et al. MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease. Skeletal Radiol 2011; doi: 10.1007/s00256-011-1199-y.
18. Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205-16. (Pubitemid 40378992)
19. Muntoni F, Bushby KD, Van Ommen G. 149th ENMC International Workshop and 1st Treat-NMD Workshop on "Planning phase I/II clinical trials using systematically delivered antisense oligonucleotides in Duchenne muscular dystrophy". Neuromuscul Disord. 2008;18:268-75.
20. Eagle M, Baudouin S, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926-9. (Pubitemid 35408673)
21. Wagner KR. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics. 2008;5:583-9.
22. Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP. A renaissance of antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol. 2009;66:32-8.
23. Muntoni F, Wels D. Genetic treatments in muscular dystrophies. Curr Opin Neurol. 2007;20:590-4. (Pubitemid 47462291)
24. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918-28.
25. Sookhoo S, Mackinnon I, Bushby K, Chinnery PF, Birchall D. MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol. 2007;62:160-5. (Pubitemid 46024209)
26. Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging. 2008;28:543-58.
27. Bernard CP, Liney GP, Manton DJ, Turnbull LW, Langton CM. Comparison of fat quantification methods: a phantom study at 3.0 T. J Magn Reson Imaging. 2008;27:192-7.